ストックスクリーナーアプリを入手
66.04
1.71%
1.11
アフターアワーズ：
66.04
前日終値:
$64.93
開ける：
$64.92
24時間の取引高:
1.61M
Relative Volume:
0.84
時価総額：
$12.78B
収益：
$4.41B
当期純損益:
$21.27M
株価収益率:
206.38
EPS:
0.32
ネットキャッシュフロー:
$288.81M
1週間 パフォーマンス:
+2.37%
1か月 パフォーマンス:
+9.28%
6か月 パフォーマンス:
-11.46%
1年 パフォーマンス:
+16.02%
1日の値動き範囲:
$64.63
$66.26
1週間の範囲:
$63.51
$66.26
52週間の値動き範囲:
$53.56
$83.95
Incyte Corp Stock (INCY) Company Profile
INCY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
66.04 | 12.49B | 4.41B | 21.27M | 288.81M | 0.32 |
|
ONC
Beone Medicines Ltd Adr
|
246.68 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.09 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 40.37M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.39 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
77.49 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-18 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-03-18 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | 開始されました | UBS | Neutral |
| 2024-10-29 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-10-01 | 開始されました | Wolfe Research | Outperform |
| 2024-09-18 | ダウングレード | Truist | Buy → Hold |
| 2024-07-02 | ダウングレード | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 開始されました | Deutsche Bank | Hold |
| 2024-04-23 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 開始されました | Jefferies | Buy |
| 2024-02-14 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-11-21 | ダウングレード | Goldman | Buy → Neutral |
| 2023-07-25 | 開始されました | Citigroup | Buy |
| 2023-05-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-04-10 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | アップグレード | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 開始されました | Piper Sandler | Overweight |
| 2022-08-03 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-08-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-07-28 | 開始されました | Wells Fargo | Equal Weight |
| 2022-02-09 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-07-20 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-02-10 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 開始されました | Truist | Buy |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-06-16 | 開始されました | The Benchmark Company | Hold |
| 2020-05-06 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-04-29 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 再開されました | William Blair | Outperform |
| 2020-03-13 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 再開されました | BofA/Merrill | Neutral |
| 2020-01-03 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2020-01-03 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-01-02 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-10-03 | 開始されました | Mizuho | Buy |
| 2019-09-12 | 開始されました | BMO Capital Markets | Market Perform |
| 2019-09-05 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 再開されました | Morgan Stanley | Equal-Weight |
| 2019-09-05 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 開始されました | Credit Suisse | Neutral |
| 2019-05-03 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 開始されました | Stifel | Hold |
| 2019-04-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | アップグレード | William Blair | Mkt Perform → Outperform |
すべてを表示
Incyte Corp (INCY) 最新ニュース
Vitiligo Market Growth Trends and Forecast Report 2025-2033Rising Awareness, Diagnostic Advances, Innovative Therapies, and Expanding Global Healthcare Access - Yahoo Finance
Incyte’s SWOT analysis: stock faces patent cliff amid pipeline potential - Investing.com
Incyte’s SWOT analysis: stock faces patent cliff amid pipeline potential By Investing.com - Investing.com India
Incyte to Present at Upcoming Investor Conference on Monday, June 9, 2025 at 11:20 am (ET) - BioSpace
Liposarcoma Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15+ Companies and 20+ Therapies | DelveInsight - GlobeNewswire Inc.
Incyte (INCY) Target Price Raised by Truist Securities | INCY St - GuruFocus
Incyte (INCY) Sees Price Target Boost from Truist Analyst | INCY Stock News - GuruFocus
Incyte to Present at Upcoming Investor Conference - Business Wire
3 Reasons INCY is Risky and 1 Stock to Buy Instead - Yahoo Finance
FDA approves Incyte’s retifanlimab combo for SCAC treatment - Yahoo Finance
Is Wall Street Bullish or Bearish on Incyte Stock? - inkl
Is Wall Street Bullish Or Bearish On Incyte Stock? - Barchart.com
Incyte Gets FDA Approval for Zynyz in New Cancer Indication - MSN
Incyte adds more FDA approvals for Zynyz in cancer - BioWorld MedTech
FDA Approves Incyte's (INCY) Zynyz for Advanced Anal Cancer Trea - GuruFocus
Incyte granted FDA approval of Zynyz for SCAC - The Pharma Letter
Incyte’s PD-1 Blocker Wins First-Line Anal Cancer Approval - BioSpace
No Article III Appellate Standing Under the Sun - Lexology
FDA Broadens Approval for Incyte's Zynyz in Cancer Treatments (INCY) - GuruFocus
FDA Approves Incyte's (INCY) Zynyz for Advanced Anal Cancer Treatment | INCY Stock News - GuruFocus
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States | INCY Stock News - GuruFocus
FDA approves new anal cancer treatment Zynyz by Incyte - Investing.com
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States – Company AnnouncementFT.com - Financial Times
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States - The Joplin Globe
Pharma Company Incyte Settles Novartis Royalties Dispute for $280 Million, SEC Records Show - Law.com
Incyte Corporation (INCY) Reaches Settlement with Novartis Over Royalty Dispute - GuruFocus
Incyte (INCY) Reaches $280M Settlement with Novartis Over Jakafi Royalties - GuruFocus
Chronic Hand Eczema Pipeline 2025: FDA Updates, Therapy - openPR.com
Chronic Hand Eczema Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis Biotherapeutics - Barchart.com
Incyte Corporation (INCY): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey
Incyte settles royalty dispute with Novartis for $280 million - Investing.com
Incyte at Bank of America Conference: Strategic Insights on Growth - Investing.com
Incyte To Present At 2025 BofA Securities Health Care Conference; Webcast At 4:40 PM ET - Nasdaq
Latest Federal Court Cases: Pharmaceutical Patent Protections - JD Supra
INCY Q1 Earnings Call: New Product Launches and Pipeline Progress Drive Outperformance - Yahoo Finance
Incyte Corporation: Here Are The 5 Major Factors Propelling Our ‘Outperform’ Rating! - Smartkarma
Steroid Refactory Acute Graft-Versus-Host Disease Market Set - openPR.com
Incyte Co. (NASDAQ:INCY) Holdings Raised by Stifel Financial Corp - Defense World
Incyte expects minimal tariff hit, lifts blood cancer drug's 2025 forecast - MSN
New Incyte Suit Targets Broader Apotex Bid to Sell Jakafi Rival - Bloomberg Law News
Sun shines on Leqselvi at Federal Circuit - BioWorld MedTech
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 7, 2025 - BioSpace
Fed. Circ. Clears Way For Sun Pharma Alopecia Drug - Law360
US panel, finding no irreparable harm, vacates injunction against Sun Pharma - MLex
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | INCY Stock News - GuruFocus
Incyte Can’t Keep Sun’s Hair Drug Off Market, Appeals Court Says - Bloomberg Law News
Chronic Hand Eczema Pipeline 2025: FDA Approvals, Therapies, - openPR.com
Novartis, Incyte Settle Drug Royalty Fight On Eve Of Trial - Law360
William Blair Has Optimistic Outlook of Incyte Q4 Earnings - Defense World
Polycythemia vera Market: Epidemiology, Therapies, - openPR.com
Alopecia Areata Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte Corp - Barchart.com
Incyte Corp (INCY) 財務データ
収益
当期純利益
現金流量
EPS
0.95%
大文字化:
|
ボリューム (24 時間):